Revelation Biosciences, Inc. (NASDAQ:REVB) experienced a 2.4% increase in its stock price during mid-day trading on Friday, with shares reaching a high of $0.99 before closing at $0.9550. This uptick came as the company reported a trading volume of 46,605 shares, significantly lower than its average of 121,422 shares, indicating a 62% decline in activity. The stock had closed at $0.9326 on the previous trading day.
Analyst Ratings and Earnings Report
In a recent analysis, Weiss Ratings reiterated a “sell (e+)” rating for Revelation Biosciences on November 24, 2023. This assessment aligns with the overall sentiment from investment analysts, as the stock currently holds an average rating of “Sell” according to data from MarketBeat.
The company’s latest quarterly earnings report, released on November 6, revealed that Revelation Biosciences reported an earnings per share (EPS) of ($1.77), which fell short of the consensus estimate of ($1.34) by $0.43. Projections suggest that the company may post an EPS of -$49.33 for the current fiscal year, reflecting ongoing challenges in meeting market expectations.
Institutional Investment Activity
Recent filings with the Securities and Exchange Commission (SEC) indicate that Armistice Capital LLC has taken a new position in Revelation Biosciences, acquiring 80,000 shares valued at approximately $114,000 during the third quarter. This new stake represents about 0.52% of the company’s total shares. Overall, institutional investors collectively hold 12.80% of Revelation Biosciences’ stock, suggesting a modest level of confidence among larger investors despite the company’s struggles.
Revelation Biosciences is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing immune system therapeutics and diagnostics. The company focuses on several therapeutic product candidates, including GEM-SSI, aimed at preventing and treating surgical site infections; GEM-AKI, targeting acute kidney injury; and GEM-CKD, which aims to address chronic kidney disease.
As Revelation Biosciences continues to navigate its financial landscape, investors will be closely watching its performance and any forthcoming developments in its product pipeline. The company’s ability to meet earnings expectations and improve investor sentiment will be crucial in the coming months.
